Briggs Morrison’s Crossbow unveils $77M Series B for T cell engagersnews2026-03-18T13:02:40+00:00March 18th, 2026|Endpoints News|
Aspen’s personalized Parkinson’s therapy shows early promisenews2026-03-18T13:00:44+00:00March 18th, 2026|Endpoints News|
Shanghai biotech Excalipoint gains $68.7M for T cell engagersnews2026-03-18T12:00:09+00:00March 18th, 2026|Endpoints News|
